Furthermore, it remains to be assessed whether alterations in the frequency or phenotype of SARS-CoV-2–specific CD4+ T cells, observed in the context of HIV and aTB coinfections, have an impact on COVID-19 clinical outcome, as the limited number of patients and the cross-sectional design of this study precluded speculation on this issue. The gene discussed is CD4; the disease is COVID-19.